hypericin has been researched along with Fibrosarcoma in 11 studies
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Histomorphological changes in murine fibrosarcoma after photodynamic therapy (PDT) based on the natural photosensitizer hypericin were evaluated." | 7.74 | Histomorphological changes in murine fibrosarcoma after hypericin-based photodynamic therapy. ( Bobrov, N; Brezáni, P; Cavarga, I; Fedorocko, P; Longauer, F; Mirossay, L; Miskovský, P; Rybárová, S; Stubna, J, 2007) |
| "Hypericin, a potent necrosis avid agent, features a peculiar affinity for necrotic tissue." | 7.74 | Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. ( De Witte, PA; Ni, Y; Van de Putte, M, 2008) |
| "To study the effect of co-injecting unlabelled hypericin (Hyp) on biodistribution, necrosis uptake and tumour retention of iodine-123 or iodine-131 labelled hypericin ((123/131)I-Hyp), a necrosis avid agent for an anticancer radiotherapy." | 3.80 | Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations. ( Chen, F; Cona, MM; Feng, Y; Li, J; Ni, Y; Oyen, R; Verbruggen, A; Witte, Pd, 2014) |
| "Thirty severe combined immunodeficiency (SCID) mice bearing bilateral radiation-induced fibrosarcoma-1 (RIF-1) subcutaneously were divided into group A of SMSDTTS with sequential intravenous injections of combretastatin A4 phosphate (CA4P) and (131)I-iodohypericin ((131)I-Hyp) at a 24 h interval; group B of single targeting control with CA4P and vehicle of (131)I-Hyp; and group C of vehicle control (10 mice per group)." | 3.79 | Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. ( Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Nuyts, J; Oyen, R; Verbruggen, A; Yu, J; Zhang, G; Zhang, J; Zhou, L, 2013) |
| "Histomorphological changes in murine fibrosarcoma after photodynamic therapy (PDT) based on the natural photosensitizer hypericin were evaluated." | 3.74 | Histomorphological changes in murine fibrosarcoma after hypericin-based photodynamic therapy. ( Bobrov, N; Brezáni, P; Cavarga, I; Fedorocko, P; Longauer, F; Mirossay, L; Miskovský, P; Rybárová, S; Stubna, J, 2007) |
| "Seven mice bearing intrahepatic radiation-induced fibrosarcoma-1 tumors were intravenously injected with hypericin 1 hour before (n = 3) or 24 hours after (n = 4) intratumoral ethanol injection." | 3.74 | Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. ( Chen, F; de Witte, PA; Ni, Y; Van de Putte, M; Wang, H, 2008) |
| "Hypericin, a potent necrosis avid agent, features a peculiar affinity for necrotic tissue." | 3.74 | Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. ( De Witte, PA; Ni, Y; Van de Putte, M, 2008) |
| " 33% fractionated dose), but the fractionated schedule of hypericin dosing was found to be more efficient than the single dose, measured by survival assay (p < 0." | 1.33 | Photoinduced antitumour effect of hypericin can be enhanced by fractionated dosing. ( Bobrov, N; Brezáni, P; Cavarga, I; Fedorocko, P; Longauer, F; Mirossay, L; Miskovský, P; Rybárova, S; Stubna, J, 2005) |
| "Hypericin is a natural photosensitizer produced in plants of the genus Hypericum." | 1.31 | Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. ( Agostinis, P; Chen, B; De Witte, PA; Xu, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 3 |
| Cona, MM | 3 |
| Chen, F | 3 |
| Feng, Y | 2 |
| Zhou, L | 1 |
| Zhang, G | 1 |
| Nuyts, J | 1 |
| de Witte, P | 1 |
| Zhang, J | 1 |
| Yu, J | 1 |
| Oyen, R | 2 |
| Verbruggen, A | 3 |
| Ni, Y | 6 |
| Witte, Pd | 1 |
| Van de Putte, M | 3 |
| Marysael, T | 1 |
| Fonge, H | 1 |
| Roskams, T | 3 |
| Bormans, G | 1 |
| de Witte, PA | 6 |
| Chen, B | 3 |
| Ahmed, B | 1 |
| Landuyt, W | 1 |
| Gaspar, R | 1 |
| Cavarga, I | 3 |
| Brezáni, P | 3 |
| Fedorocko, P | 3 |
| Miskovský, P | 3 |
| Bobrov, N | 2 |
| Longauer, F | 2 |
| Rybárova, S | 2 |
| Mirossay, L | 2 |
| Stubna, J | 2 |
| Wang, H | 1 |
| Xu, Y | 2 |
| Agostinis, P | 2 |
| Cekanová-Figurová, M | 1 |
| Solár, P | 1 |
11 other studies available for hypericin and Fibrosarcoma
| Article | Year |
|---|---|
Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
Topics: Administration, Intravenous; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Fi | 2013 |
Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Carriers; Fi | 2014 |
Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential.
Topics: Animals; Anthracenes; Autoradiography; Female; Fibrosarcoma; Fluorodeoxyglucose F18; Mice; Mice, Inb | 2012 |
Potentiation of photodynamic therapy with hypericin by mitomycin C in the radiation-induced fibrosarcoma-1 mouse tumor model.
Topics: Animals; Anthracenes; Disease Models, Animal; Drug Synergism; Female; Fibrosarcoma; Mice; Mitomycin; | 2003 |
Photoinduced antitumour effect of hypericin can be enhanced by fractionated dosing.
Topics: Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Administration Sched | 2005 |
Histomorphological changes in murine fibrosarcoma after hypericin-based photodynamic therapy.
Topics: Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; F | 2007 |
Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model.
Topics: Analysis of Variance; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Ethanol; | 2008 |
Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.
Topics: Animals; Anthracenes; Carbocyanines; Female; Fibrosarcoma; Lipoproteins; Mice; Mice, Inbred C3H; Nec | 2008 |
Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells.
Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Cell Death; Combined Modality Therapy; Drug Syne | 2001 |
Photodynamic therapy of murine fibrosarcoma with topical and systemic administration of hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents, Phytogenic; Fibrosarcoma; Light; Male; Mice; Mice, Inbr | 2001 |
Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model.
Topics: Animals; Anthracenes; Apoptosis; Blood Vessels; Cell Nucleus; Cell Survival; DNA Fragmentation; Dose | 2002 |